Immunotherapies targeting the CTLA-4 pathway have shown remarkable clinical efficacy against many cancer types, such as prostate, cervical, gastric, pancreatic, ovarian, and urothelial cancers and melanoma50,51. Here, CTLA4 is linked to cancer.